ChemicalName,ChemicalID,PathwayName,PathwayID,PValue,CorrectedPValue,TargetMatchQty,TargetTotalQty,BackgroundMatchQty,BackgroundTotalQty
10074-G5,C534883,,Cyclin A:Cdk2-associated events at S phase entry,REACT:R-HSA-69656,1.45e-05,0.00116,2,4,71
10074-G5,C534883,,Cyclin E associated events during G1/S transition,REACT:R-HSA-69202,1.49e-05,0.00119,2,4,72
10074-G5,C534883,,G1/S Transition,REACT:R-HSA-69206,4.08e-05,0.00327,2,4,119
10074-G5,C534883,,Mitotic G1-G1/S phases,REACT:R-HSA-453279,5.9e-05,0.00472,2,4,143
10074-G5,C534883,,Pathways in cancer,KEGG:hsa05200,2.61e-06,0.000209,3,4,395
10074-G5,C534883,,Small cell lung cancer,KEGG:hsa05222,2.03e-05,0.00162,2,4,84
10074-G5,C534883,,S Phase,REACT:R-HSA-69242,4.88e-05,0.0039,2,4,130
10074-G5,C534883,,Transcriptional misregulation in cancer,KEGG:hsa05202,9.25e-05,0.0074,2,4,179
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,,Cholinergic synapse,KEGG:hsa04725,3.53e-11,2.93e-09,4,4,112
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,,Interaction between L1 and Ankyrins,REACT:R-HSA-445095,2.54e-06,0.000211,2,4,30
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,,L1CAM interactions,REACT:R-HSA-373760,2.94e-05,0.00244,2,4,101
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,,Neuronal System,REACT:R-HSA-112316,1.8e-06,0.000149,3,4,349
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,,Potassium Channels,REACT:R-HSA-1296071,4.16e-08,3.45e-06,3,4,100
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,,Voltage gated Potassium channels,REACT:R-HSA-1296072,3.41e-09,2.83e-07,3,4,44
"10,12-octadecadienoic acid",C094849,,AMPK signaling pathway,KEGG:hsa04152,2.08e-05,0.00164,2,3,120
"10,12-octadecadienoic acid",C094849,,"Fatty acid, triacylglycerol, and ketone body metabolism",REACT:R-HSA-535734,9.2e-05,0.00727,2,3,252
"10,12-octadecadienoic acid",C094849,,Huntington's disease,KEGG:hsa05016,5.39e-05,0.00426,2,3,193
"10,12-octadecadienoic acid",C094849,,PPAR signaling pathway,KEGG:hsa03320,7.45e-06,0.000589,2,3,72
10-(2-pyrazolylethoxy)camptothecin,C534422,,Alzheimer's disease,KEGG:hsa05010,1.41e-05,0.0013,2,2,171
10-(2-pyrazolylethoxy)camptothecin,C534422,,Apoptosis,KEGG:hsa04210,9.2e-06,0.000846,2,2,138
10-(2-pyrazolylethoxy)camptothecin,C534422,,Apoptosis,REACT:R-HSA-109581,1.43e-05,0.00132,2,2,172
10-(2-pyrazolylethoxy)camptothecin,C534422,,Apoptosis - multiple species,KEGG:hsa04215,5.14e-07,4.73e-05,2,2,33
10-(2-pyrazolylethoxy)camptothecin,C534422,,Apoptotic cleavage of cellular proteins,REACT:R-HSA-111465,7.21e-07,6.63e-05,2,2,39
10-(2-pyrazolylethoxy)camptothecin,C534422,,Apoptotic execution  phase,REACT:R-HSA-75153,1.34e-06,0.000123,2,2,53
10-(2-pyrazolylethoxy)camptothecin,C534422,,Caspase activation via extrinsic apoptotic signalling pathway,REACT:R-HSA-5357769,3.68e-07,3.38e-05,2,2,28
10-(2-pyrazolylethoxy)camptothecin,C534422,,Caspase-mediated cleavage of cytoskeletal proteins,REACT:R-HSA-264870,7.59e-08,6.98e-06,2,2,13
10-(2-pyrazolylethoxy)camptothecin,C534422,,Hepatitis B,KEGG:hsa05161,1e-05,0.000922,2,2,144
10-(2-pyrazolylethoxy)camptothecin,C534422,,Herpes simplex infection,KEGG:hsa05168,1.66e-05,0.00152,2,2,185
10-(2-pyrazolylethoxy)camptothecin,C534422,,Huntington's disease,KEGG:hsa05016,1.8e-05,0.00166,2,2,193
10-(2-pyrazolylethoxy)camptothecin,C534422,,IL-17 signaling pathway,KEGG:hsa04657,4.16e-06,0.000383,2,2,93
10-(2-pyrazolylethoxy)camptothecin,C534422,,Intrinsic Pathway for Apoptosis,REACT:R-HSA-109606,9.2e-07,8.47e-05,2,2,44
10-(2-pyrazolylethoxy)camptothecin,C534422,,Legionellosis,KEGG:hsa05134,1.44e-06,0.000133,2,2,55
10-(2-pyrazolylethoxy)camptothecin,C534422,,Non-alcoholic fatty liver disease (NAFLD),KEGG:hsa04932,1.07e-05,0.000987,2,2,149
10-(2-pyrazolylethoxy)camptothecin,C534422,,p53 signaling pathway,KEGG:hsa04115,2.28e-06,0.00021,2,2,69
10-(2-pyrazolylethoxy)camptothecin,C534422,,Pathways in cancer,KEGG:hsa05200,7.57e-05,0.00697,2,2,395
10-(2-pyrazolylethoxy)camptothecin,C534422,,Platinum drug resistance,KEGG:hsa01524,2.56e-06,0.000235,2,2,73
10-(2-pyrazolylethoxy)camptothecin,C534422,,Programmed Cell Death,REACT:R-HSA-5357801,1.48e-05,0.00136,2,2,175
10-(2-pyrazolylethoxy)camptothecin,C534422,,TNF signaling pathway,KEGG:hsa04668,5.62e-06,0.000517,2,2,108
10-(2-pyrazolylethoxy)camptothecin,C534422,,Toxoplasmosis,KEGG:hsa05145,6.16e-06,0.000566,2,2,113
10-(2-pyrazolylethoxy)camptothecin,C534422,,Tuberculosis,KEGG:hsa05152,1.53e-05,0.00141,2,2,178
10-(2-pyrazolylethoxy)camptothecin,C534422,,Viral carcinogenesis,KEGG:hsa05203,1.96e-05,0.0018,2,2,201
10-(2-pyrazolylethoxy)camptothecin,C534422,,Viral myocarditis,KEGG:hsa05416,1.61e-06,0.000148,2,2,58
103D5R,C496879,,Activated TLR4 signalling,REACT:R-HSA-166054,5.52e-07,0.000212,3,7,115
103D5R,C496879,,Activation of BH3-only proteins,REACT:R-HSA-114452,9.48e-06,0.00364,2,7,31
103D5R,C496879,,Activation of the AP-1 family of transcription factors,REACT:R-HSA-450341,2.7e-10,1.04e-07,3,7,10
103D5R,C496879,,Acute myeloid leukemia,KEGG:hsa05221,5.89e-08,2.26e-05,3,7,55
103D5R,C496879,,Adipocytokine signaling pathway,KEGG:hsa04920,1.18e-07,4.51e-05,3,7,69
103D5R,C496879,,Adrenergic signaling in cardiomyocytes,KEGG:hsa04261,1.09e-06,0.000418,3,7,144
103D5R,C496879,,Advanced glycosylation endproduct receptor signaling,REACT:R-HSA-879415,1.59e-06,0.000611,2,7,13
103D5R,C496879,,AGE-RAGE signaling pathway in diabetic complications,KEGG:hsa04933,9.38e-13,3.6e-10,5,7,99
103D5R,C496879,,Aldosterone-regulated sodium reabsorption,KEGG:hsa04960,1.36e-05,0.00521,2,7,37
103D5R,C496879,,Apelin signaling pathway,KEGG:hsa04371,9.57e-07,0.000367,3,7,138
103D5R,C496879,,Apoptosis,KEGG:hsa04210,2.85e-09,1.1e-06,4,7,138
103D5R,C496879,,Autophagy - animal,KEGG:hsa04140,3.46e-12,1.33e-09,5,7,128
103D5R,C496879,,B cell receptor signaling pathway,KEGG:hsa04662,1.23e-07,4.72e-05,3,7,70
103D5R,C496879,,Bladder cancer,KEGG:hsa05219,2.4e-08,9.2e-06,3,7,41
103D5R,C496879,,Breast cancer,KEGG:hsa05224,1.09e-06,0.000418,3,7,144
103D5R,C496879,,cAMP signaling pathway,KEGG:hsa04024,1.22e-08,4.69e-06,4,7,198
103D5R,C496879,,Cellular responses to stress,REACT:R-HSA-2262752,1.97e-09,7.56e-07,5,7,451
103D5R,C496879,,Cellular Senescence,REACT:R-HSA-2559583,2.75e-06,0.00106,3,7,196
103D5R,C496879,,Central carbon metabolism in cancer,KEGG:hsa05230,1.08e-13,4.16e-11,5,7,65
103D5R,C496879,,cGMP-PKG signaling pathway,KEGG:hsa04022,1.58e-06,0.000607,3,7,163
103D5R,C496879,,Chagas disease (American trypanosomiasis),KEGG:hsa05142,8.4e-10,3.23e-07,4,7,102
103D5R,C496879,,Chemokine signaling pathway,KEGG:hsa04062,2.2e-06,0.000845,3,7,182
103D5R,C496879,,Choline metabolism in cancer,KEGG:hsa05231,9.38e-13,3.6e-10,5,7,99
103D5R,C496879,,Cholinergic synapse,KEGG:hsa04725,5.1e-07,0.000196,3,7,112
103D5R,C496879,,Chronic myeloid leukemia,KEGG:hsa05220,1.28e-07,4.92e-05,3,7,71
103D5R,C496879,,Colorectal cancer,KEGG:hsa05210,9.67e-11,3.71e-08,4,7,60
103D5R,C496879,,Cytokine Signaling in Immune system,REACT:R-HSA-1280215,2.67e-08,1.02e-05,5,7,760
103D5R,C496879,,DAP12 interactions,REACT:R-HSA-2172127,1.86e-05,0.00713,3,7,371
103D5R,C496879,,DAP12 signaling,REACT:R-HSA-2424491,1.64e-05,0.0063,3,7,356
103D5R,C496879,,Developmental Biology,REACT:R-HSA-1266738,1.04e-05,0.004,4,7,1076
103D5R,C496879,,Diseases of signal transduction,REACT:R-HSA-5663202,1.83e-05,0.00701,3,7,369
103D5R,C496879,,Dorso-ventral axis formation,KEGG:hsa04320,7.71e-06,0.00296,2,7,28
103D5R,C496879,,Downstream signaling events of B Cell Receptor (BCR),REACT:R-HSA-1168372,2.79e-06,0.00107,3,7,197
103D5R,C496879,,Downstream signal transduction,REACT:R-HSA-186763,1.59e-05,0.00609,3,7,352
103D5R,C496879,,EGFR tyrosine kinase inhibitor resistance,KEGG:hsa01521,2.98e-10,1.14e-07,4,7,79
103D5R,C496879,,Endocrine resistance,KEGG:hsa01522,6.3e-10,2.42e-07,4,7,95
103D5R,C496879,,Endometrial cancer,KEGG:hsa05213,4.4e-08,1.69e-05,3,7,50
103D5R,C496879,,ErbB signaling pathway,KEGG:hsa04012,4.2e-10,1.61e-07,4,7,86
103D5R,C496879,,ERK/MAPK targets,REACT:R-HSA-198753,4.71e-06,0.00181,2,7,22
103D5R,C496879,,ERKs are inactivated,REACT:R-HSA-202670,1.59e-06,0.000611,2,7,13
103D5R,C496879,,Estrogen signaling pathway,KEGG:hsa04915,3.41e-07,0.000131,3,7,98
103D5R,C496879,,Fc epsilon receptor (FCERI) signaling,REACT:R-HSA-2454202,1.63e-07,6.27e-05,4,7,378
103D5R,C496879,,Fc epsilon RI signaling pathway,KEGG:hsa04664,1.52e-10,5.83e-08,4,7,67
103D5R,C496879,,FCERI mediated MAPK activation,REACT:R-HSA-2871796,7.26e-06,0.00279,3,7,271
103D5R,C496879,,Fc gamma R-mediated phagocytosis,KEGG:hsa04666,2.63e-07,0.000101,3,7,90
103D5R,C496879,,Fluid shear stress and atherosclerosis,KEGG:hsa05418,1.04e-06,0.000401,3,7,142
103D5R,C496879,,Focal adhesion,KEGG:hsa04510,3.23e-11,1.24e-08,5,7,199
103D5R,C496879,,FoxO signaling pathway,KEGG:hsa04068,2.39e-09,9.16e-07,4,7,132
103D5R,C496879,,GAB1 signalosome,REACT:R-HSA-180292,7.63e-07,0.000293,3,7,128
103D5R,C496879,,Glioma,KEGG:hsa05214,9.35e-08,3.59e-05,3,7,64
103D5R,C496879,,GnRH signaling pathway,KEGG:hsa04912,2.81e-07,0.000108,3,7,92
103D5R,C496879,,Golgi Cisternae Pericentriolar Stack Reorganization,REACT:R-HSA-162658,1.86e-06,0.000713,2,7,14
103D5R,C496879,,Growth hormone receptor signaling,REACT:R-HSA-982772,6.12e-06,0.00235,2,7,25
103D5R,C496879,,Hemostasis,REACT:R-HSA-109582,1.32e-06,0.000508,4,7,639
103D5R,C496879,,Hepatitis B,KEGG:hsa05161,3.39e-09,1.3e-06,4,7,144
103D5R,C496879,,Hepatitis C,KEGG:hsa05160,2.31e-09,8.88e-07,4,7,131
103D5R,C496879,,HIF-1 signaling pathway,KEGG:hsa04066,7.34e-16,2.82e-13,6,7,101
103D5R,C496879,,HTLV-I infection,KEGG:hsa05166,6.12e-06,0.00235,3,7,256
103D5R,C496879,,IGF1R signaling cascade,REACT:R-HSA-2428924,9.65e-06,0.0037,3,7,298
103D5R,C496879,,IL-17 signaling pathway,KEGG:hsa04657,2.91e-07,0.000112,3,7,93
103D5R,C496879,,Immune System,REACT:R-HSA-168256,6.94e-08,2.66e-05,6,7,2118
103D5R,C496879,,Influenza A,KEGG:hsa05164,7.1e-09,2.73e-06,4,7,173
103D5R,C496879,,Innate Immune System,REACT:R-HSA-168249,2.18e-05,0.00839,4,7,1298
103D5R,C496879,,Insulin receptor signalling cascade,REACT:R-HSA-74751,9.55e-06,0.00367,3,7,297
103D5R,C496879,,Insulin resistance,KEGG:hsa04931,4.44e-07,0.000171,3,7,107
103D5R,C496879,,Insulin signaling pathway,KEGG:hsa04910,2.85e-09,1.1e-06,4,7,138
103D5R,C496879,,Interleukin-4 and 13 signaling,REACT:R-HSA-6785807,5.38e-07,0.000207,3,7,114
103D5R,C496879,,Intrinsic Pathway for Apoptosis,REACT:R-HSA-109606,1.93e-05,0.0074,2,7,44
103D5R,C496879,,IRS-mediated signalling,REACT:R-HSA-112399,9.27e-06,0.00356,3,7,294
103D5R,C496879,,IRS-related events triggered by IGF1R,REACT:R-HSA-2428928,9.65e-06,0.0037,3,7,298
103D5R,C496879,,MAP2K and MAPK activation,REACT:R-HSA-5674135,1.51e-05,0.0058,2,7,39
103D5R,C496879,,MAPK (ERK1/2) signaling,KEGG:hsa_M00687,5.72e-07,0.00022,2,7,8
103D5R,C496879,,MAP kinase activation in TLR cascade,REACT:R-HSA-450294,9.35e-08,3.59e-05,3,7,64
103D5R,C496879,,MAPK signaling pathway,KEGG:hsa04010,3.38e-08,1.3e-05,4,7,255
103D5R,C496879,,MAPK targets/ Nuclear events mediated by MAP kinases,REACT:R-HSA-450282,1.01e-08,3.88e-06,3,7,31
103D5R,C496879,,Melanoma,KEGG:hsa05218,1.18e-07,4.51e-05,3,7,69
103D5R,C496879,,mTOR signaling pathway,KEGG:hsa04150,1.26e-06,0.000482,3,7,151
103D5R,C496879,,MyD88 cascade initiated on plasma membrane,REACT:R-HSA-975871,2.14e-07,8.2e-05,3,7,84
103D5R,C496879,,MyD88 dependent cascade initiated on endosome,REACT:R-HSA-975155,2.91e-07,0.000112,3,7,93
103D5R,C496879,,MyD88-independent TLR3/TLR4 cascade,REACT:R-HSA-166166,3.51e-07,0.000135,3,7,99
103D5R,C496879,,MyD88:Mal cascade initiated on plasma membrane,REACT:R-HSA-166058,3.1e-07,0.000119,3,7,95
103D5R,C496879,,Negative feedback regulation of MAPK pathway,REACT:R-HSA-5674499,3.06e-07,0.000118,2,7,6
103D5R,C496879,,Negative regulation of FGFR1 signaling,REACT:R-HSA-5654726,1.08e-05,0.00413,2,7,33
103D5R,C496879,,Negative regulation of FGFR2 signaling,REACT:R-HSA-5654727,1.14e-05,0.00439,2,7,34
103D5R,C496879,,Negative regulation of FGFR3 signaling,REACT:R-HSA-5654732,8.28e-06,0.00318,2,7,29
103D5R,C496879,,Negative regulation of FGFR4 signaling,REACT:R-HSA-5654733,9.48e-06,0.00364,2,7,31
103D5R,C496879,,Negative regulation of MAPK pathway,REACT:R-HSA-5675221,1.59e-05,0.0061,2,7,40
103D5R,C496879,,Negative regulation of the PI3K/AKT network,REACT:R-HSA-199418,3e-07,0.000115,3,7,94
103D5R,C496879,,Neurotrophin signaling pathway,KEGG:hsa04722,1.57e-09,6.03e-07,4,7,119
103D5R,C496879,,NGF signalling via TRKA from the plasma membrane,REACT:R-HSA-187037,2.11e-05,0.00808,3,7,387
103D5R,C496879,,NOD-like receptor signaling pathway,KEGG:hsa04621,1.79e-06,0.000688,3,7,170
103D5R,C496879,,Non-small cell lung cancer,KEGG:hsa05223,6.93e-08,2.66e-05,3,7,58
103D5R,C496879,,Nuclear Events (kinase and transcription factor activation),REACT:R-HSA-198725,6.12e-06,0.00235,2,7,25
103D5R,C496879,,Oncogene Induced Senescence,REACT:R-HSA-2559585,1.01e-05,0.00388,2,7,32
103D5R,C496879,,Osteoclast differentiation,KEGG:hsa04380,2.17e-09,8.35e-07,4,7,129
103D5R,C496879,,Oxidative Stress Induced Senescence,REACT:R-HSA-2559580,7.27e-07,0.000279,3,7,126
103D5R,C496879,,Pancreatic cancer,KEGG:hsa05212,1e-13,3.84e-11,5,7,64
103D5R,C496879,,Paradoxical activation of RAF signaling by kinase inactive BRAF,REACT:R-HSA-6802955,1.51e-05,0.0058,2,7,39
103D5R,C496879,,Pathways in cancer,KEGG:hsa05200,3.61e-15,1.39e-12,7,7,395
103D5R,C496879,,Pertussis,KEGG:hsa05133,1.58e-07,6.05e-05,3,7,76
103D5R,C496879,,Phospholipase D signaling pathway,KEGG:hsa04072,1.11e-06,0.000427,3,7,145
103D5R,C496879,,PI3K/AKT activation,REACT:R-HSA-198203,7.63e-07,0.000293,3,7,128
103D5R,C496879,,PI3K-Akt signaling pathway,KEGG:hsa04151,1.08e-07,4.15e-05,4,7,341
103D5R,C496879,,"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",REACT:R-HSA-6811558,2.38e-07,9.12e-05,3,7,87
103D5R,C496879,,PIP3 activates AKT signaling,REACT:R-HSA-1257604,7.1e-07,0.000273,3,7,125
103D5R,C496879,,Platelet activation,KEGG:hsa04611,6.76e-07,0.00026,3,7,123
103D5R,C496879,,"Platelet activation, signaling and aggregation",REACT:R-HSA-76002,5.05e-08,1.94e-05,4,7,282
103D5R,C496879,,Platinum drug resistance,KEGG:hsa01524,1.39e-07,5.36e-05,3,7,73
103D5R,C496879,,Prion diseases,KEGG:hsa05020,1.21e-05,0.00466,2,7,35
103D5R,C496879,,Progesterone-mediated oocyte maturation,KEGG:hsa04914,6.57e-10,2.52e-07,4,7,96
103D5R,C496879,,Prolactin signaling pathway,KEGG:hsa04917,1.82e-10,6.97e-08,4,7,70
103D5R,C496879,,Prostate cancer,KEGG:hsa05215,2.38e-07,9.12e-05,3,7,87
103D5R,C496879,,Proteoglycans in cancer,KEGG:hsa05205,3.57e-11,1.37e-08,5,7,203
103D5R,C496879,,RAF-independent MAPK1/3 activation,REACT:R-HSA-112409,5.16e-06,0.00198,2,7,23
103D5R,C496879,,Rap1 signaling pathway,KEGG:hsa04015,1.55e-08,5.95e-06,4,7,210
103D5R,C496879,,Ras signaling pathway,KEGG:hsa04014,6.27e-11,2.41e-08,5,7,227
103D5R,C496879,,Regulation of gene expression by Hypoxia-inducible Factor,REACT:R-HSA-1234158,1.35e-06,0.000517,2,7,12
103D5R,C496879,,Renal cell carcinoma,KEGG:hsa05211,4.79e-17,1.84e-14,6,7,65
103D5R,C496879,,Retrograde endocannabinoid signaling,KEGG:hsa04723,3.73e-07,0.000143,3,7,101
103D5R,C496879,,RHO GTPases Activate WASPs and WAVEs,REACT:R-HSA-5663213,1.28e-05,0.00493,2,7,36
103D5R,C496879,,Role of LAT2/NTAL/LAB on calcium mobilization,REACT:R-HSA-2730905,9.36e-07,0.00036,3,7,137
103D5R,C496879,,Salmonella infection,KEGG:hsa05132,2.29e-07,8.81e-05,3,7,86
103D5R,C496879,,Shigellosis,KEGG:hsa05131,9.35e-08,3.59e-05,3,7,64
103D5R,C496879,,Signal attenuation,REACT:R-HSA-74749,9.19e-07,0.000353,2,7,10
103D5R,C496879,,Signaling by EGFR,REACT:R-HSA-177929,1.75e-05,0.00673,3,7,364
103D5R,C496879,,Signaling by FGFR1,REACT:R-HSA-5654736,2.49e-05,0.00958,2,7,50
103D5R,C496879,,Signaling by FGFR3,REACT:R-HSA-5654741,1.59e-05,0.0061,2,7,40
103D5R,C496879,,Signaling by FGFR4,REACT:R-HSA-5654743,1.67e-05,0.00641,2,7,41
103D5R,C496879,,Signaling by high-kinase activity BRAF mutants,REACT:R-HSA-6802948,1.21e-05,0.00466,2,7,35
103D5R,C496879,,Signaling by Insulin receptor,REACT:R-HSA-74752,1.22e-05,0.00467,3,7,322
103D5R,C496879,,Signaling by Interleukins,REACT:R-HSA-449147,4.33e-09,1.66e-06,5,7,528
103D5R,C496879,,Signaling by moderate kinase activity BRAF mutants,REACT:R-HSA-6802946,1.51e-05,0.0058,2,7,39
103D5R,C496879,,Signaling by PDGF,REACT:R-HSA-186797,1.93e-05,0.00742,3,7,376
103D5R,C496879,,Signaling by RAS mutants,REACT:R-HSA-6802949,2.49e-05,0.00958,2,7,50
103D5R,C496879,,Signaling by SCF-KIT,REACT:R-HSA-1433557,1.39e-05,0.00535,3,7,337
103D5R,C496879,,Signaling by the B Cell Receptor (BCR),REACT:R-HSA-983705,4.68e-06,0.0018,3,7,234
103D5R,C496879,,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),REACT:R-HSA-2404192,9.74e-06,0.00374,3,7,299
103D5R,C496879,,Signaling by VEGF,REACT:R-HSA-194138,1.04e-07,4.01e-05,4,7,338
103D5R,C496879,,Signaling pathways regulating pluripotency of stem cells,KEGG:hsa04550,9.78e-07,0.000376,3,7,139
103D5R,C496879,,Signalling by NGF,REACT:R-HSA-166520,4.13e-07,0.000159,4,7,477
103D5R,C496879,,Signal Transduction,REACT:R-HSA-162582,2.3e-07,8.84e-05,6,7,2590
103D5R,C496879,,Signal transduction by L1,REACT:R-HSA-445144,4.28e-06,0.00165,2,7,21
103D5R,C496879,,Sphingolipid signaling pathway,KEGG:hsa04071,1.52e-09,5.82e-07,4,7,118
103D5R,C496879,,Spry regulation of FGF signaling,REACT:R-HSA-1295596,2.45e-06,0.000941,2,7,16
103D5R,C496879,,T cell receptor signaling pathway,KEGG:hsa04660,3.96e-07,0.000152,3,7,103
103D5R,C496879,,Th17 cell differentiation,KEGG:hsa04659,1.02e-09,3.92e-07,4,7,107
103D5R,C496879,,Th1 and Th2 cell differentiation,KEGG:hsa04658,2.81e-07,0.000108,3,7,92
103D5R,C496879,,Thrombin signalling through proteinase activated receptors (PARs),REACT:R-HSA-456926,1.01e-05,0.00388,2,7,32
103D5R,C496879,,Thyroid cancer,KEGG:hsa05216,8.28e-06,0.00318,2,7,29
103D5R,C496879,,Thyroid hormone signaling pathway,KEGG:hsa04919,2.1e-12,8.07e-10,5,7,116
103D5R,C496879,,TNF signaling pathway,KEGG:hsa04668,1.06e-09,4.07e-07,4,7,108
103D5R,C496879,,Toll Like Receptor 10 (TLR10) Cascade,REACT:R-HSA-168142,2.14e-07,8.2e-05,3,7,84
103D5R,C496879,,Toll Like Receptor 2 (TLR2) Cascade,REACT:R-HSA-181438,3.1e-07,0.000119,3,7,95
103D5R,C496879,,Toll Like Receptor 3 (TLR3) Cascade,REACT:R-HSA-168164,3.51e-07,0.000135,3,7,99
103D5R,C496879,,Toll Like Receptor 4 (TLR4) Cascade,REACT:R-HSA-166016,7.27e-07,0.000279,3,7,126
103D5R,C496879,,Toll Like Receptor 5 (TLR5) Cascade,REACT:R-HSA-168176,2.14e-07,8.2e-05,3,7,84
103D5R,C496879,,Toll Like Receptor 7/8 (TLR7/8) Cascade,REACT:R-HSA-168181,2.91e-07,0.000112,3,7,93
103D5R,C496879,,Toll Like Receptor 9 (TLR9) Cascade,REACT:R-HSA-168138,3.3e-07,0.000127,3,7,97
103D5R,C496879,,Toll-Like Receptors Cascades,REACT:R-HSA-168898,1.31e-06,0.000501,3,7,153
103D5R,C496879,,Toll-like receptor signaling pathway,KEGG:hsa04620,9.09e-10,3.49e-07,4,7,104
103D5R,C496879,,Toll Like Receptor TLR1:TLR2 Cascade,REACT:R-HSA-168179,3.1e-07,0.000119,3,7,95
103D5R,C496879,,Toll Like Receptor TLR6:TLR2 Cascade,REACT:R-HSA-168188,3.1e-07,0.000119,3,7,95
103D5R,C496879,,Toxoplasmosis,KEGG:hsa05145,1.27e-09,4.89e-07,4,7,113
103D5R,C496879,,TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,REACT:R-HSA-975138,2.72e-07,0.000105,3,7,91
103D5R,C496879,,TRIF-mediated TLR3/TLR4 signaling,REACT:R-HSA-937061,3.51e-07,0.000135,3,7,99
103D5R,C496879,,Tuberculosis,KEGG:hsa05152,7.96e-09,3.06e-06,4,7,178
103D5R,C496879,,Type II diabetes mellitus,KEGG:hsa04930,3.41e-08,1.31e-05,3,7,46
103D5R,C496879,,VEGFA-VEGFR2 Pathway,REACT:R-HSA-4420097,9.48e-08,3.64e-05,4,7,330
103D5R,C496879,,VEGFR2 mediated cell proliferation,REACT:R-HSA-5218921,6.27e-06,0.00241,3,7,258
103D5R,C496879,,VEGF signaling pathway,KEGG:hsa04370,9.02e-11,3.46e-08,4,7,59
10-(4'-(N-diethylamino)butyl)-2-chlorophenoxazine,C553100,,Arrhythmogenic right ventricular cardiomyopathy (ARVC),KEGG:hsa05412,3.71e-05,0.00371,2,6,72
10-(4'-(N-diethylamino)butyl)-2-chlorophenoxazine,C553100,,Dilated cardiomyopathy,KEGG:hsa05414,5.69e-05,0.00569,2,6,89
10-(4'-(N-diethylamino)butyl)-2-chlorophenoxazine,C553100,,ECM proteoglycans,REACT:R-HSA-3000178,2.32e-05,0.00232,2,6,57
10-(4'-(N-diethylamino)butyl)-2-chlorophenoxazine,C553100,,ECM-receptor interaction,KEGG:hsa04512,1.14e-07,1.14e-05,3,6,82
10-(4'-(N-diethylamino)butyl)-2-chlorophenoxazine,C553100,,GRB2:SOS provides linkage to MAPK signaling for Integrins,REACT:R-HSA-354194,1.75e-06,0.000175,2,6,16
10-(4'-(N-diethylamino)butyl)-2-chlorophenoxazine,C553100,,Hematopoietic cell lineage,KEGG:hsa04640,2.29e-13,2.29e-11,5,6,96
10-(4'-(N-diethylamino)butyl)-2-chlorophenoxazine,C553100,,Hemostasis,REACT:R-HSA-109582,3.25e-09,3.25e-07,5,6,639
10-(4'-(N-diethylamino)butyl)-2-chlorophenoxazine,C553100,,Hypertrophic cardiomyopathy (HCM),KEGG:hsa05410,4.94e-05,0.00494,2,6,83
10-(4'-(N-diethylamino)butyl)-2-chlorophenoxazine,C553100,,Integrin alphaIIb beta3 signaling,REACT:R-HSA-354192,5.51e-06,0.000551,2,6,28
10-(4'-(N-diethylamino)butyl)-2-chlorophenoxazine,C553100,,Integrin cell surface interactions,REACT:R-HSA-216083,3.31e-05,0.00331,2,6,68
10-(4'-(N-diethylamino)butyl)-2-chlorophenoxazine,C553100,,L1CAM interactions,REACT:R-HSA-373760,7.33e-05,0.00733,2,6,101
10-(4'-(N-diethylamino)butyl)-2-chlorophenoxazine,C553100,,MAP2K and MAPK activation,REACT:R-HSA-5674135,1.08e-05,0.00108,2,6,39
10-(4'-(N-diethylamino)butyl)-2-chlorophenoxazine,C553100,,Oncogenic MAPK signaling,REACT:R-HSA-6802957,3.93e-05,0.00393,2,6,74
10-(4'-(N-diethylamino)butyl)-2-chlorophenoxazine,C553100,,p130Cas linkage to MAPK signaling for integrins,REACT:R-HSA-372708,1.75e-06,0.000175,2,6,16
10-(4'-(N-diethylamino)butyl)-2-chlorophenoxazine,C553100,,Paradoxical activation of RAF signaling by kinase inactive BRAF,REACT:R-HSA-6802955,1.08e-05,0.00108,2,6,39
10-(4'-(N-diethylamino)butyl)-2-chlorophenoxazine,C553100,,Platelet activation,KEGG:hsa04611,3.87e-07,3.87e-05,3,6,123
10-(4'-(N-diethylamino)butyl)-2-chlorophenoxazine,C553100,,"Platelet activation, signaling and aggregation",REACT:R-HSA-76002,2.18e-08,2.18e-06,4,6,282
10-(4'-(N-diethylamino)butyl)-2-chlorophenoxazine,C553100,,Platelet Aggregation (Plug Formation),REACT:R-HSA-76009,6.28e-12,6.28e-10,4,6,38
10-(4'-(N-diethylamino)butyl)-2-chlorophenoxazine,C553100,,Signaling by BRAF and RAF fusions,REACT:R-HSA-6802952,2.57e-05,0.00257,2,6,60
10-(4'-(N-diethylamino)butyl)-2-chlorophenoxazine,C553100,,Signaling by high-kinase activity BRAF mutants,REACT:R-HSA-6802948,8.67e-06,0.000867,2,6,35
10-(4'-(N-diethylamino)butyl)-2-chlorophenoxazine,C553100,,Signaling by moderate kinase activity BRAF mutants,REACT:R-HSA-6802946,1.08e-05,0.00108,2,6,39
10-(4'-(N-diethylamino)butyl)-2-chlorophenoxazine,C553100,,Signaling by RAS mutants,REACT:R-HSA-6802949,1.78e-05,0.00178,2,6,50
10-(4'-(N-diethylamino)butyl)-2-chlorophenoxazine,C553100,,Signal transduction by L1,REACT:R-HSA-445144,3.06e-06,0.000306,2,6,21
10-decarbamoylmitomycin C,C067795,26909-37-5,Activation of caspases through apoptosome-mediated cleavage,REACT:R-HSA-111459,9.73e-08,2.1e-05,2,5,5
10-decarbamoylmitomycin C,C067795,26909-37-5,AKT phosphorylates targets in the cytosol,REACT:R-HSA-198323,7.59e-07,0.000164,2,5,13
10-decarbamoylmitomycin C,C067795,26909-37-5,Amyotrophic lateral sclerosis (ALS),KEGG:hsa05014,1.34e-08,2.89e-06,3,5,51
10-decarbamoylmitomycin C,C067795,26909-37-5,Apoptosis,REACT:R-HSA-109581,5.33e-07,0.000115,3,5,172
10-decarbamoylmitomycin C,C067795,26909-37-5,Apoptosis,KEGG:hsa04210,2.75e-07,5.93e-05,3,5,138
10-decarbamoylmitomycin C,C067795,26909-37-5,Apoptosis - multiple species,KEGG:hsa04215,5.13e-06,0.00111,2,5,33
10-decarbamoylmitomycin C,C067795,26909-37-5,Apoptotic factor-mediated response,REACT:R-HSA-111471,2.04e-07,4.41e-05,2,5,7
10-decarbamoylmitomycin C,C067795,26909-37-5,Apoptotic machinery,KEGG:hsa_M00685,5.84e-08,1.26e-05,2,5,4
10-decarbamoylmitomycin C,C067795,26909-37-5,Bladder cancer,KEGG:hsa05219,7.96e-06,0.00172,2,5,41
10-decarbamoylmitomycin C,C067795,26909-37-5,Caspase activation via extrinsic apoptotic signalling pathway,REACT:R-HSA-5357769,3.67e-06,0.000793,2,5,28
10-decarbamoylmitomycin C,C067795,26909-37-5,Cell cycle,KEGG:hsa04110,1.99e-07,4.3e-05,3,5,124
10-decarbamoylmitomycin C,C067795,26909-37-5,Cell Cycle,REACT:R-HSA-1640170,2.51e-05,0.00541,3,5,621
10-decarbamoylmitomycin C,C067795,26909-37-5,Cell Cycle Checkpoints,REACT:R-HSA-69620,8.53e-07,0.000184,3,5,201
10-decarbamoylmitomycin C,C067795,26909-37-5,Chronic myeloid leukemia,KEGG:hsa05220,2.41e-05,0.00521,2,5,71
10-decarbamoylmitomycin C,C067795,26909-37-5,Colorectal cancer,KEGG:hsa05210,2.2e-08,4.75e-06,3,5,60
10-decarbamoylmitomycin C,C067795,26909-37-5,Constitutive Signaling by AKT1 E17K in Cancer,REACT:R-HSA-5674400,2.92e-06,0.00063,2,5,25
10-decarbamoylmitomycin C,C067795,26909-37-5,Cytochrome c-mediated apoptotic response,REACT:R-HSA-111461,9.73e-08,2.1e-05,2,5,5
10-decarbamoylmitomycin C,C067795,26909-37-5,Cytokine Signaling in Immune system,REACT:R-HSA-1280215,4.57e-05,0.00988,3,5,760
10-decarbamoylmitomycin C,C067795,26909-37-5,DAP12 interactions,REACT:R-HSA-2172127,5.37e-06,0.00116,3,5,371
10-decarbamoylmitomycin C,C067795,26909-37-5,DAP12 signaling,REACT:R-HSA-2424491,4.74e-06,0.00102,3,5,356
10-decarbamoylmitomycin C,C067795,26909-37-5,DNA Damage/Telomere Stress Induced Senescence,REACT:R-HSA-2559586,2.99e-05,0.00645,2,5,79
10-decarbamoylmitomycin C,C067795,26909-37-5,Downstream signaling events of B Cell Receptor (BCR),REACT:R-HSA-1168372,8.03e-07,0.000173,3,5,197
10-decarbamoylmitomycin C,C067795,26909-37-5,Downstream signal transduction,REACT:R-HSA-186763,4.59e-06,0.000991,3,5,352
10-decarbamoylmitomycin C,C067795,26909-37-5,Endocrine resistance,KEGG:hsa01522,4.33e-05,0.00934,2,5,95
10-decarbamoylmitomycin C,C067795,26909-37-5,Endometrial cancer,KEGG:hsa05213,1.19e-05,0.00257,2,5,50
10-decarbamoylmitomycin C,C067795,26909-37-5,Fc epsilon receptor (FCERI) signaling,REACT:R-HSA-2454202,5.68e-06,0.00123,3,5,378
10-decarbamoylmitomycin C,C067795,26909-37-5,G1/S DNA Damage Checkpoints,REACT:R-HSA-69615,3.08e-08,6.65e-06,3,5,67
10-decarbamoylmitomycin C,C067795,26909-37-5,G2/M DNA damage checkpoint,REACT:R-HSA-69473,4.33e-05,0.00934,2,5,95
10-decarbamoylmitomycin C,C067795,26909-37-5,GAB1 signalosome,REACT:R-HSA-180292,2.19e-07,4.73e-05,3,5,128
10-decarbamoylmitomycin C,C067795,26909-37-5,Glioma,KEGG:hsa05214,1.96e-05,0.00423,2,5,64
10-decarbamoylmitomycin C,C067795,26909-37-5,Hepatitis B,KEGG:hsa05161,4.87e-10,1.05e-07,4,5,144
10-decarbamoylmitomycin C,C067795,26909-37-5,HTLV-I infection,KEGG:hsa05166,1.76e-06,0.000381,3,5,256
10-decarbamoylmitomycin C,C067795,26909-37-5,Huntington's disease,KEGG:hsa05016,7.55e-07,0.000163,3,5,193
10-decarbamoylmitomycin C,C067795,26909-37-5,Immune System,REACT:R-HSA-168256,2.29e-05,0.00494,4,5,2118
10-decarbamoylmitomycin C,C067795,26909-37-5,Intrinsic Pathway for Apoptosis,REACT:R-HSA-109606,8.51e-09,1.84e-06,3,5,44
10-decarbamoylmitomycin C,C067795,26909-37-5,Legionellosis,KEGG:hsa05134,1.44e-05,0.00311,2,5,55
10-decarbamoylmitomycin C,C067795,26909-37-5,Ligand-independent caspase activation via DCC,REACT:R-HSA-418889,5.35e-07,0.000116,2,5,11
10-decarbamoylmitomycin C,C067795,26909-37-5,Melanoma,KEGG:hsa05218,2.28e-05,0.00492,2,5,69
10-decarbamoylmitomycin C,C067795,26909-37-5,MicroRNAs in cancer,KEGG:hsa05206,2.81e-06,0.000607,3,5,299
10-decarbamoylmitomycin C,C067795,26909-37-5,NGF signalling via TRKA from the plasma membrane,REACT:R-HSA-187037,6.09e-06,0.00132,3,5,387
10-decarbamoylmitomycin C,C067795,26909-37-5,Non-small cell lung cancer,KEGG:hsa05223,1.6e-05,0.00347,2,5,58
10-decarbamoylmitomycin C,C067795,26909-37-5,p53-Dependent G1 DNA Damage Response,REACT:R-HSA-69563,2.02e-05,0.00436,2,5,65
10-decarbamoylmitomycin C,C067795,26909-37-5,p53-Dependent G1/S DNA damage checkpoint,REACT:R-HSA-69580,2.02e-05,0.00436,2,5,65
10-decarbamoylmitomycin C,C067795,26909-37-5,p53 signaling pathway,KEGG:hsa04115,7.04e-15,1.52e-12,5,5,69
10-decarbamoylmitomycin C,C067795,26909-37-5,Pancreatic cancer,KEGG:hsa05212,1.96e-05,0.00423,2,5,64
10-decarbamoylmitomycin C,C067795,26909-37-5,Pathways in cancer,KEGG:hsa05200,2.82e-08,6.09e-06,4,5,395
10-decarbamoylmitomycin C,C067795,26909-37-5,PI3K/AKT activation,REACT:R-HSA-198203,2.19e-07,4.73e-05,3,5,128
10-decarbamoylmitomycin C,C067795,26909-37-5,PI3K/AKT Signaling in Cancer,REACT:R-HSA-2219528,3.88e-05,0.00838,2,5,90
10-decarbamoylmitomycin C,C067795,26909-37-5,PI3K-Akt signaling pathway,KEGG:hsa04151,4.17e-06,0.000901,3,5,341
10-decarbamoylmitomycin C,C067795,26909-37-5,PIP3 activates AKT signaling,REACT:R-HSA-1257604,2.04e-07,4.4e-05,3,5,125
10-decarbamoylmitomycin C,C067795,26909-37-5,Platinum drug resistance,KEGG:hsa01524,3.09e-11,6.67e-09,4,5,73
10-decarbamoylmitomycin C,C067795,26909-37-5,Programmed Cell Death,REACT:R-HSA-5357801,5.62e-07,0.000121,3,5,175
10-decarbamoylmitomycin C,C067795,26909-37-5,Prostate cancer,KEGG:hsa05215,6.8e-08,1.47e-05,3,5,87
10-decarbamoylmitomycin C,C067795,26909-37-5,Proteoglycans in cancer,KEGG:hsa05205,8.79e-07,0.00019,3,5,203
10-decarbamoylmitomycin C,C067795,26909-37-5,Regulation of TP53 Activity through Phosphorylation,REACT:R-HSA-6804756,4.15e-05,0.00895,2,5,93
10-decarbamoylmitomycin C,C067795,26909-37-5,Role of LAT2/NTAL/LAB on calcium mobilization,REACT:R-HSA-2730905,2.69e-07,5.8e-05,3,5,137
10-decarbamoylmitomycin C,C067795,26909-37-5,Signaling by EGFR,REACT:R-HSA-177929,5.07e-06,0.0011,3,5,364
10-decarbamoylmitomycin C,C067795,26909-37-5,Signaling by Interleukins,REACT:R-HSA-449147,1.54e-05,0.00333,3,5,528
10-decarbamoylmitomycin C,C067795,26909-37-5,Signaling by PDGF,REACT:R-HSA-186797,5.59e-06,0.00121,3,5,376
10-decarbamoylmitomycin C,C067795,26909-37-5,Signaling by SCF-KIT,REACT:R-HSA-1433557,1.49e-08,3.22e-06,4,5,337
10-decarbamoylmitomycin C,C067795,26909-37-5,Signaling by the B Cell Receptor (BCR),REACT:R-HSA-983705,1.35e-06,0.000291,3,5,234
10-decarbamoylmitomycin C,C067795,26909-37-5,Signalling by NGF,REACT:R-HSA-166520,6e-08,1.3e-05,4,5,477
10-decarbamoylmitomycin C,C067795,26909-37-5,Signal Transduction,REACT:R-HSA-162582,6.06e-07,0.000131,5,5,2590
10-decarbamoylmitomycin C,C067795,26909-37-5,SMAC binds to IAPs,REACT:R-HSA-111463,9.73e-08,2.1e-05,2,5,5
10-decarbamoylmitomycin C,C067795,26909-37-5,SMAC-mediated apoptotic response,REACT:R-HSA-111469,9.73e-08,2.1e-05,2,5,5
10-decarbamoylmitomycin C,C067795,26909-37-5,SMAC-mediated dissociation of IAP:caspase complexes,REACT:R-HSA-111464,9.73e-08,2.1e-05,2,5,5
10-decarbamoylmitomycin C,C067795,26909-37-5,Small cell lung cancer,KEGG:hsa05222,3.38e-05,0.0073,2,5,84
10-decarbamoylmitomycin C,C067795,26909-37-5,The role of GTSE1 in G2/M progression after G2 checkpoint,REACT:R-HSA-8852276,1.78e-05,0.00384,2,5,61
10-decarbamoylmitomycin C,C067795,26909-37-5,TP53 Regulates Transcription of Cell Cycle Genes,REACT:R-HSA-6791312,1.14e-05,0.00247,2,5,49
10-decarbamoylmitomycin C,C067795,26909-37-5,TP53 Regulates Transcription of DNA Repair Genes,REACT:R-HSA-6796648,2.28e-05,0.00492,2,5,69
10-decarbamoylmitomycin C,C067795,26909-37-5,TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest,REACT:R-HSA-6804116,7.59e-07,0.000164,2,5,13
10-decarbamoylmitomycin C,C067795,26909-37-5,Transcriptional  activation of  cell cycle inhibitor p21,REACT:R-HSA-69895,5.84e-08,1.26e-05,2,5,4
10-decarbamoylmitomycin C,C067795,26909-37-5,Transcriptional activation of p53 responsive genes,REACT:R-HSA-69560,5.84e-08,1.26e-05,2,5,4
10-decarbamoylmitomycin C,C067795,26909-37-5,Transcriptional Regulation by TP53,REACT:R-HSA-3700989,5.33e-06,0.00115,3,5,370
10-decarbamoylmitomycin C,C067795,26909-37-5,Viral carcinogenesis,KEGG:hsa05203,1.87e-09,4.03e-07,4,5,201
10-decarbamoylmitomycin C,C067795,26909-37-5,Viral myocarditis,KEGG:hsa05416,1.6e-05,0.00347,2,5,58
10-(fluoroethoxyphosphinyl)-N-(biotinamidopentyl)decanamide,C403065,,Metabolism,REACT:R-HSA-1430728,2.13e-06,0.000185,6,10,2171
10-(fluoroethoxyphosphinyl)-N-(biotinamidopentyl)decanamide,C403065,,Mitochondrial protein import,REACT:R-HSA-1268020,8.22e-05,0.00715,2,10,62
10-(fluoroethoxyphosphinyl)-N-(biotinamidopentyl)decanamide,C403065,,Neurotransmitter Clearance In The Synaptic Cleft,REACT:R-HSA-112311,1.97e-06,0.000171,2,10,10
10-(fluoroethoxyphosphinyl)-N-(biotinamidopentyl)decanamide,C403065,,Synthesis of PC,REACT:R-HSA-1483191,1.65e-05,0.00144,2,10,28
10-(fluoroethoxyphosphinyl)-N-(biotinamidopentyl)decanamide,C403065,,"Synthesis, secretion, and deacylation of Ghrelin",REACT:R-HSA-422085,7.47e-06,0.00065,2,10,19
"10H-3,6-diazaphenothiazine",C000627785,,Alzheimer's disease,KEGG:hsa05010,8.44e-05,0.00929,2,4,171
"10H-3,6-diazaphenothiazine",C000627785,,Apoptosis,REACT:R-HSA-109581,2.14e-07,2.35e-05,3,4,172
"10H-3,6-diazaphenothiazine",C000627785,,Apoptosis,KEGG:hsa04210,8.21e-11,9.04e-09,4,4,138
"10H-3,6-diazaphenothiazine",C000627785,,Apoptosis - multiple species,KEGG:hsa04215,3.08e-06,0.000339,2,4,33
"10H-3,6-diazaphenothiazine",C000627785,,Apoptotic cleavage of cellular proteins,REACT:R-HSA-111465,4.32e-06,0.000475,2,4,39
"10H-3,6-diazaphenothiazine",C000627785,,Apoptotic execution  phase,REACT:R-HSA-75153,8.03e-06,0.000884,2,4,53
"10H-3,6-diazaphenothiazine",C000627785,,Caspase activation via extrinsic apoptotic signalling pathway,REACT:R-HSA-5357769,2.2e-06,0.000243,2,4,28
"10H-3,6-diazaphenothiazine",C000627785,,Caspase-mediated cleavage of cytoskeletal proteins,REACT:R-HSA-264870,4.55e-07,5.01e-05,2,4,13
"10H-3,6-diazaphenothiazine",C000627785,,Hepatitis B,KEGG:hsa05161,5.99e-05,0.00658,2,4,144
"10H-3,6-diazaphenothiazine",C000627785,,Intrinsic Pathway for Apoptosis,REACT:R-HSA-109606,5.52e-06,0.000607,2,4,44
"10H-3,6-diazaphenothiazine",C000627785,,Legionellosis,KEGG:hsa05134,8.66e-06,0.000952,2,4,55
"10H-3,6-diazaphenothiazine",C000627785,,NOD1/2 Signaling Pathway,REACT:R-HSA-168638,1.28e-09,1.4e-07,3,4,32
"10H-3,6-diazaphenothiazine",C000627785,,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",REACT:R-HSA-168643,4.45e-09,4.9e-07,3,4,48
"10H-3,6-diazaphenothiazine",C000627785,,p53 signaling pathway,KEGG:hsa04115,1.37e-05,0.0015,2,4,69
"10H-3,6-diazaphenothiazine",C000627785,,Platinum drug resistance,KEGG:hsa01524,1.53e-05,0.00168,2,4,73
"10H-3,6-diazaphenothiazine",C000627785,,Programmed Cell Death,REACT:R-HSA-5357801,2.25e-07,2.48e-05,3,4,175
"10H-3,6-diazaphenothiazine",C000627785,,Toxoplasmosis,KEGG:hsa05145,3.68e-05,0.00405,2,4,113
"10H-3,6-diazaphenothiazine",C000627785,,TP53 Regulates Transcription of Caspase Activators and Caspases,REACT:R-HSA-6803207,3.85e-07,4.24e-05,2,4,12
"10H-3,6-diazaphenothiazine",C000627785,,TP53 Regulates Transcription of Cell Death Genes,REACT:R-HSA-5633008,5.77e-06,0.000635,2,4,45
"10H-3,6-diazaphenothiazine",C000627785,,Viral myocarditis,KEGG:hsa05416,9.63e-06,0.00106,2,4,58
10-hydroxycamptothecin,C028098,67656-30-8,AGE-RAGE signaling pathway in diabetic complications,KEGG:hsa04933,4.7e-05,0.00728,2,5,99
10-hydroxycamptothecin,C028098,67656-30-8,Amyotrophic lateral sclerosis (ALS),KEGG:hsa05014,1.34e-08,2.07e-06,3,5,51
10-hydroxycamptothecin,C028098,67656-30-8,Apoptosis,REACT:R-HSA-109581,5.33e-07,8.27e-05,3,5,172
10-hydroxycamptothecin,C028098,67656-30-8,Apoptosis,KEGG:hsa04210,4.1e-10,6.35e-08,4,5,138
10-hydroxycamptothecin,C028098,67656-30-8,Apoptosis - multiple species,KEGG:hsa04215,3.51e-09,5.44e-07,3,5,33
10-hydroxycamptothecin,C028098,67656-30-8,BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members,REACT:R-HSA-111453,3.5e-07,5.43e-05,2,5,9
10-hydroxycamptothecin,C028098,67656-30-8,Chronic myeloid leukemia,KEGG:hsa05220,2.41e-05,0.00374,2,5,71
10-hydroxycamptothecin,C028098,67656-30-8,Colorectal cancer,KEGG:hsa05210,1.72e-05,0.00266,2,5,60
10-hydroxycamptothecin,C028098,67656-30-8,Cytokine Signaling in Immune system,REACT:R-HSA-1280215,4.57e-05,0.00709,3,5,760
10-hydroxycamptothecin,C028098,67656-30-8,EGFR tyrosine kinase inhibitor resistance,KEGG:hsa01521,2.99e-05,0.00463,2,5,79
10-hydroxycamptothecin,C028098,67656-30-8,Endocrine resistance,KEGG:hsa01522,4.33e-05,0.00671,2,5,95
10-hydroxycamptothecin,C028098,67656-30-8,Immune System,REACT:R-HSA-168256,2.29e-05,0.00354,4,5,2118
10-hydroxycamptothecin,C028098,67656-30-8,Inflammasomes,REACT:R-HSA-622312,1.32e-06,0.000205,2,5,17
10-hydroxycamptothecin,C028098,67656-30-8,Interleukin-4 and 13 signaling,REACT:R-HSA-6785807,6.24e-05,0.00967,2,5,114
10-hydroxycamptothecin,C028098,67656-30-8,Intrinsic Pathway for Apoptosis,REACT:R-HSA-109606,8.51e-09,1.32e-06,3,5,44
10-hydroxycamptothecin,C028098,67656-30-8,MicroRNAs in cancer,KEGG:hsa05206,2.81e-06,0.000436,3,5,299
10-hydroxycamptothecin,C028098,67656-30-8,NF-kappa B signaling pathway,KEGG:hsa04064,4.24e-05,0.00656,2,5,94
10-hydroxycamptothecin,C028098,67656-30-8,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",REACT:R-HSA-168643,1.1e-05,0.0017,2,5,48
10-hydroxycamptothecin,C028098,67656-30-8,p53 signaling pathway,KEGG:hsa04115,2.28e-05,0.00353,2,5,69
10-hydroxycamptothecin,C028098,67656-30-8,Pathways in cancer,KEGG:hsa05200,2.82e-08,4.37e-06,4,5,395
10-hydroxycamptothecin,C028098,67656-30-8,PI3K-Akt signaling pathway,KEGG:hsa04151,4.17e-06,0.000646,3,5,341
10-hydroxycamptothecin,C028098,67656-30-8,Platinum drug resistance,KEGG:hsa01524,3.09e-11,4.79e-09,4,5,73
10-hydroxycamptothecin,C028098,67656-30-8,Programmed Cell Death,REACT:R-HSA-5357801,5.62e-07,8.71e-05,3,5,175
10-hydroxycamptothecin,C028098,67656-30-8,Prostate cancer,KEGG:hsa05215,3.63e-05,0.00562,2,5,87
10-hydroxycamptothecin,C028098,67656-30-8,Signaling by Interleukins,REACT:R-HSA-449147,1.54e-05,0.00239,3,5,528
10-hydroxycamptothecin,C028098,67656-30-8,Small cell lung cancer,KEGG:hsa05222,3.38e-05,0.00524,2,5,84
10-hydroxycamptothecin,C028098,67656-30-8,The NLRP1 inflammasome,REACT:R-HSA-844455,2.92e-08,4.52e-06,2,5,3
10-hydroxycamptothecin,C028098,67656-30-8,Toxoplasmosis,KEGG:hsa05145,1.5e-07,2.33e-05,3,5,113
10-hydroxycamptothecin,C028098,67656-30-8,Transcriptional misregulation in cancer,KEGG:hsa05202,6.02e-07,9.32e-05,3,5,179
10-hydroxywarfarin,C065719,83219-99-2,Biological oxidations,REACT:R-HSA-211859,4.68e-07,1.45e-05,3,4,223
10-hydroxywarfarin,C065719,83219-99-2,Chemical carcinogenesis,KEGG:hsa05204,2.28e-08,7.06e-07,3,4,82
10-hydroxywarfarin,C065719,83219-99-2,Cytochrome P450 - arranged by substrate type,REACT:R-HSA-211897,1.33e-05,0.000411,2,4,68
10-hydroxywarfarin,C065719,83219-99-2,Drug metabolism - cytochrome P450,KEGG:hsa00982,1.35e-08,4.18e-07,3,4,69
10-hydroxywarfarin,C065719,83219-99-2,Drug metabolism - other enzymes,KEGG:hsa00983,6.03e-06,0.000187,2,4,46
10-hydroxywarfarin,C065719,83219-99-2,Linoleic acid metabolism,KEGG:hsa00591,2.37e-06,7.34e-05,2,4,29
10-hydroxywarfarin,C065719,83219-99-2,Metabolic pathways,KEGG:hsa01100,8.57e-05,0.00266,3,4,1269
10-hydroxywarfarin,C065719,83219-99-2,Metabolism of xenobiotics by cytochrome P450,KEGG:hsa00980,1.6e-08,4.96e-07,3,4,73
10-hydroxywarfarin,C065719,83219-99-2,Phase 1 - Functionalization of compounds,REACT:R-HSA-211945,3.43e-05,0.00106,2,4,109
10-hydroxywarfarin,C065719,83219-99-2,Retinol metabolism,KEGG:hsa00830,1.12e-08,3.48e-07,3,4,65
10-hydroxywarfarin,C065719,83219-99-2,Steroid hormone biosynthesis,KEGG:hsa00140,9.63e-06,0.000299,2,4,58
10-hydroxywarfarin,C065719,83219-99-2,Xenobiotics,REACT:R-HSA-211981,1.75e-06,5.43e-05,2,4,25
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,"Activation, myristolyation of BID and translocation to mitochondria",REACT:R-HSA-75108,5.31e-07,0.000113,2,14,4
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Activation of BAD and translocation to mitochondria,REACT:R-HSA-111447,9.27e-06,0.00198,2,14,15
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Activation of BH3-only proteins,REACT:R-HSA-114452,4.1e-05,0.00872,2,14,31
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Activation of caspases through apoptosome-mediated cleavage,REACT:R-HSA-111459,2.34e-10,4.99e-08,3,14,5
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,"Activation, translocation and oligomerization of BAX",REACT:R-HSA-114294,8.85e-08,1.89e-05,2,14,2
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,AGE-RAGE signaling pathway in diabetic complications,KEGG:hsa04933,3.61e-06,0.000769,3,14,99
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Alzheimer's disease,KEGG:hsa05010,3.22e-14,6.86e-12,7,14,171
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Amyotrophic lateral sclerosis (ALS),KEGG:hsa05014,5.06e-18,1.08e-15,7,14,51
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Apoptosis,REACT:R-HSA-109581,2.96e-31,6.3e-29,13,14,172
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Apoptosis,KEGG:hsa04210,2.97e-36,6.32e-34,14,14,138
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Apoptosis - multiple species,KEGG:hsa04215,1.69e-33,3.6e-31,11,14,33
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Apoptotic factor-mediated response,REACT:R-HSA-111471,2.63e-17,5.61e-15,5,14,7
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Apoptotic machinery,KEGG:hsa_M00685,5.31e-07,0.000113,2,14,4
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members,REACT:R-HSA-111453,1.97e-09,4.19e-07,3,14,9
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,CASP8 activity is inhibited,REACT:R-HSA-5218900,1.87e-12,3.99e-10,4,14,11
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Caspase activation via extrinsic apoptotic signalling pathway,REACT:R-HSA-5357769,9.35e-17,1.99e-14,6,14,28
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Caspase-mediated cleavage of cytoskeletal proteins,REACT:R-HSA-264870,6.89e-06,0.00147,2,14,13
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Chagas disease (American trypanosomiasis),KEGG:hsa05142,2.37e-08,5.06e-06,4,14,102
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Colorectal cancer,KEGG:hsa05210,6.79e-12,1.45e-09,5,14,60
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Cytochrome c-mediated apoptotic response,REACT:R-HSA-111461,2.34e-10,4.99e-08,3,14,5
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Death Receptor Signalling,REACT:R-HSA-73887,2.64e-12,5.62e-10,5,14,50
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Dimerization of procaspase-8,REACT:R-HSA-69416,1.87e-12,3.99e-10,4,14,11
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,EGFR tyrosine kinase inhibitor resistance,KEGG:hsa01521,1.83e-06,0.000389,3,14,79
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,FasL/ CD95L signaling,REACT:R-HSA-75157,2.84e-14,6.05e-12,4,14,5
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Formation of apoptosome,REACT:R-HSA-111458,2.66e-07,5.66e-05,2,14,3
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Generic Transcription Pathway,REACT:R-HSA-212436,4.51e-06,0.00096,5,14,872
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Hepatitis B,KEGG:hsa05161,5.04e-20,1.07e-17,9,14,144
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Herpes simplex infection,KEGG:hsa05168,1.24e-11,2.65e-09,6,14,185
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Huntington's disease,KEGG:hsa05016,2.57e-09,5.48e-07,5,14,193
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,IL-17 signaling pathway,KEGG:hsa04657,2.99e-06,0.000637,3,14,93
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Immune System,REACT:R-HSA-168256,1.23e-06,0.000263,7,14,2118
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Inflammasomes,REACT:R-HSA-622312,1.2e-05,0.00256,2,14,17
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Influenza A,KEGG:hsa05164,1.99e-07,4.24e-05,4,14,173
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Innate Immune System,REACT:R-HSA-168249,3.08e-05,0.00656,5,14,1298
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Interleukin-4 and 13 signaling,REACT:R-HSA-6785807,5.52e-06,0.00118,3,14,114
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Intrinsic Pathway for Apoptosis,REACT:R-HSA-109606,2.45e-28,5.22e-26,10,14,44
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Legionellosis,KEGG:hsa05134,1.92e-09,4.09e-07,4,14,55
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Ligand-dependent caspase activation,REACT:R-HSA-140534,1.35e-11,2.88e-09,4,14,17
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Ligand-independent caspase activation via DCC,REACT:R-HSA-418889,4.86e-06,0.00104,2,14,11
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Natural killer cell mediated cytotoxicity,KEGG:hsa04650,6.72e-08,1.43e-05,4,14,132
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Neurotrophin signaling pathway,KEGG:hsa04722,6.28e-06,0.00134,3,14,119
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,NF-kappa B signaling pathway,KEGG:hsa04064,1.71e-08,3.63e-06,4,14,94
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10,REACT:R-HSA-933543,6.89e-06,0.00147,2,14,13
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,NOD1/2 Signaling Pathway,REACT:R-HSA-168638,4.37e-05,0.0093,2,14,32
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,NOD-like receptor signaling pathway,KEGG:hsa04621,1.36e-09,2.9e-07,5,14,170
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Non-alcoholic fatty liver disease (NAFLD),KEGG:hsa04932,1.21e-14,2.57e-12,7,14,149
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",REACT:R-HSA-168643,1.1e-09,2.34e-07,4,14,48
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,p53 signaling pathway,KEGG:hsa04115,4.7e-17,1e-14,7,14,69
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Parkinson's disease,KEGG:hsa05012,1.07e-05,0.00227,3,14,142
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Pathways in cancer,KEGG:hsa05200,1.4499999999999998e-23,3.0900000000000003e-21,12,14,395
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,PI3K-Akt signaling pathway,KEGG:hsa04151,2.97e-06,0.000632,4,14,341
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Platinum drug resistance,KEGG:hsa01524,1.0600000000000001e-32,2.2599999999999998e-30,12,14,73
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Programmed Cell Death,REACT:R-HSA-5357801,3.74e-31,7.960000000000001e-29,13,14,175
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Proteoglycans in cancer,KEGG:hsa05205,3.1e-05,0.00661,3,14,203
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Regulated Necrosis,REACT:R-HSA-5218859,5.47e-15,1.16e-12,5,14,16
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Regulation by c-FLIP,REACT:R-HSA-3371378,1.87e-12,3.99e-10,4,14,11
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Regulation of necroptotic cell death,REACT:R-HSA-5675482,2.51e-15,5.34e-13,5,14,14
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Regulation of TNFR1 signaling,REACT:R-HSA-5357905,4.65e-05,0.0099,2,14,33
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Release of apoptotic factors from the mitochondria,REACT:R-HSA-111457,8.85e-08,1.89e-05,2,14,2
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,RIPK1-mediated regulated necrosis,REACT:R-HSA-5213460,5.47e-15,1.16e-12,5,14,16
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Signaling by Interleukins,REACT:R-HSA-449147,1.66e-05,0.00353,4,14,528
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Signal Transduction,REACT:R-HSA-162582,2.47e-07,5.26e-05,8,14,2590
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,SMAC binds to IAPs,REACT:R-HSA-111463,2.84e-14,6.05e-12,4,14,5
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,SMAC-mediated apoptotic response,REACT:R-HSA-111469,2.84e-14,6.05e-12,4,14,5
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,SMAC-mediated dissociation of IAP:caspase complexes,REACT:R-HSA-111464,2.84e-14,6.05e-12,4,14,5
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Small cell lung cancer,KEGG:hsa05222,3.82e-11,8.14e-09,5,14,84
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Sphingolipid signaling pathway,KEGG:hsa04071,6.13e-06,0.0013,3,14,118
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,The NLRP1 inflammasome,REACT:R-HSA-844455,2.66e-07,5.66e-05,2,14,3
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,TNFR1-induced proapoptotic signaling,REACT:R-HSA-5357786,6.89e-06,0.00147,2,14,13
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,TNF signaling,REACT:R-HSA-75893,2.87e-07,6.12e-05,3,14,43
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,TNF signaling pathway,KEGG:hsa04668,2.99e-08,6.37e-06,4,14,108
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Toxoplasmosis,KEGG:hsa05145,1.67e-15,3.56e-13,7,14,113
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,TP53 Regulates Transcription of Cell Death Genes,REACT:R-HSA-5633008,3.3e-07,7.03e-05,3,14,45
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,TP53 Regulates Transcription of Genes Involved in Cytochrome C Release,REACT:R-HSA-6803204,1.85e-05,0.00395,2,14,21
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,TRAIL  signaling,REACT:R-HSA-75158,1.86e-06,0.000396,2,14,7
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Transcriptional Regulation by TP53,REACT:R-HSA-3700989,4.09e-06,0.000872,4,14,370
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,TRIF-mediated programmed cell death,REACT:R-HSA-2562578,3.98e-06,0.000847,2,14,10
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Tuberculosis,KEGG:hsa05152,1.42e-16,3.02e-14,8,14,178
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Viral carcinogenesis,KEGG:hsa05203,3.01e-05,0.00642,3,14,201
"10-methoxy-2,2-dimethyl-2,6-dihydropyrano(3,2-c)quinolin-5-one",C554291,,Viral myocarditis,KEGG:hsa05416,5.7e-12,1.21e-09,5,14,58
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,African trypanosomiasis,KEGG:hsa05143,3.27e-06,0.000556,2,4,34
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,AGE-RAGE signaling pathway in diabetic complications,KEGG:hsa04933,2.14e-11,3.63e-09,4,4,99
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Amoebiasis,KEGG:hsa05146,3.56e-08,6.05e-06,3,4,95
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Amyotrophic lateral sclerosis (ALS),KEGG:hsa05014,7.43e-06,0.00126,2,4,51
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Antifolate resistance,KEGG:hsa01523,2.71e-06,0.000461,2,4,31
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Chagas disease (American trypanosomiasis),KEGG:hsa05142,2.41e-11,4.1e-09,4,4,102
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Cytokine-cytokine receptor interaction,KEGG:hsa04060,8.32e-07,0.000141,3,4,270
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Cytokine Signaling in Immune system,REACT:R-HSA-1280215,1.85e-05,0.00315,3,4,760
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Epithelial cell signaling in Helicobacter pylori infection,KEGG:hsa05120,1.33e-05,0.00226,2,4,68
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Fc epsilon RI signaling pathway,KEGG:hsa04664,1.29e-05,0.00219,2,4,67
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Fluid shear stress and atherosclerosis,KEGG:hsa05418,1.2e-07,2.04e-05,3,4,142
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Graft-versus-host disease,KEGG:hsa05332,4.78e-06,0.000813,2,4,41
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Hematopoietic cell lineage,KEGG:hsa04640,2.65e-05,0.00451,2,4,96
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Hepatitis C,KEGG:hsa05160,9.41e-08,1.6e-05,3,4,131
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,IL-17 signaling pathway,KEGG:hsa04657,1.66e-11,2.82e-09,4,4,93
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Immune System,REACT:R-HSA-168256,4.75e-06,0.000807,4,4,2118
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Inflammatory bowel disease (IBD),KEGG:hsa05321,1.21e-05,0.00206,2,4,65
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Inflammatory mediator regulation of TRP channels,KEGG:hsa04750,2.71e-05,0.00461,2,4,97
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Influenza A,KEGG:hsa05164,2.05e-10,3.48e-08,4,4,173
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Interleukin-10 signaling,REACT:R-HSA-6783783,4.74e-09,8.06e-07,3,4,49
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Interleukin-4 and 13 signaling,REACT:R-HSA-6785807,6.18e-08,1.05e-05,3,4,114
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Legionellosis,KEGG:hsa05134,6.75e-09,1.15e-06,3,4,55
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Leishmaniasis,KEGG:hsa05140,1.53e-08,2.61e-06,3,4,72
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Malaria,KEGG:hsa05144,4.74e-09,8.06e-07,3,4,49
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,MAPK signaling pathway,KEGG:hsa04010,7e-07,0.000119,3,4,255
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,NF-kappa B signaling pathway,KEGG:hsa04064,3.45e-08,5.86e-06,3,4,94
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,NOD-like receptor signaling pathway,KEGG:hsa04621,1.91e-10,3.24e-08,4,4,170
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Non-alcoholic fatty liver disease (NAFLD),KEGG:hsa04932,1.39e-07,2.36e-05,3,4,149
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Osteoclast differentiation,KEGG:hsa04380,8.98e-08,1.53e-05,3,4,129
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Pertussis,KEGG:hsa05133,7.29e-12,1.24e-09,4,4,76
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Rheumatoid arthritis,KEGG:hsa05323,2.92e-08,4.96e-06,3,4,89
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,RIG-I-like receptor signaling pathway,KEGG:hsa04622,1.41e-08,2.39e-06,3,4,70
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Salmonella infection,KEGG:hsa05132,2.63e-08,4.47e-06,3,4,86
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Shigellosis,KEGG:hsa05131,1.17e-05,0.002,2,4,64
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Signaling by Interleukins,REACT:R-HSA-449147,6.23e-06,0.00106,3,4,528
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Sphingolipid signaling pathway,KEGG:hsa04071,4.02e-05,0.00683,2,4,118
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,T cell receptor signaling pathway,KEGG:hsa04660,3.06e-05,0.0052,2,4,103
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Th17 cell differentiation,KEGG:hsa04659,3.3e-05,0.00561,2,4,107
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,TNF signaling pathway,KEGG:hsa04668,5.25e-08,8.92e-06,3,4,108
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Toll-like receptor signaling pathway,KEGG:hsa04620,2.61e-11,4.44e-09,4,4,104
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Toxoplasmosis,KEGG:hsa05145,3.68e-05,0.00626,2,4,113
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Tuberculosis,KEGG:hsa05152,2.37e-07,4.03e-05,3,4,178
"10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-(1,4)diazepino(5',6'-4,5)thieno(3,2-f)quinolin-8-one",C549914,,Type I diabetes mellitus,KEGG:hsa04940,5.26e-06,0.000895,2,4,43
